Can-Fite BioPharma Ltd. Market Cap 2011-2026 | CANF

As of April 13, 2026 Can-Fite BioPharma Ltd. has a market cap of $ 6.35 B

Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.^[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Can-Fite BioPharma Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
4.81 M	3.16 B	2.74 B	2.07 B	647 M	706 M	185 M	700 M	1.22 B	775 M	757 M	847 M	34.6 M	25.6 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.16 B	4.81 M	990 M

References

Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer	Market Cap	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	315 M	-	2.43 %	$ 254 M	Germany
Nanobiotix S.A. NBTX	262 B	$ 30.34	-0.82 %	$ 286 B	France
I-Mab IMAB	127 M	-	-	$ 866 M	China
AlloVir ALVR	13.1 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	22.1 M	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	33.6 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	168 B	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	549 M	-	-13.47 %	$ 169 M	France
Applied Therapeutics APLT	541 M	-	-	$ 8.42 M	USA
BioNTech SE BNTX	62.9 B	$ 95.5	3.83 %	$ 27.2 B	Germany
EyeGate Pharmaceuticals, Inc. EYEG	28.9 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	79 M	-	-18.52 %	$ 27.3 M	Britain
Amphastar Pharmaceuticals AMPH	1.25 B	$ 20.37	-2.4 %	$ 952 M	USA
Acorda Therapeutics ACOR	16.7 M	-	-24.86 %	$ 820 K	USA
Институт стволовых клеток человека ISKJ	2.83 B	-	-	-	Russia
Adverum Biotechnologies ADVM	76.4 M	-	-	$ 86.2 M	USA
Advaxis ADXS	1.87 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	41.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	14.1 K	-	-10.17 %	$ 12.2 K	USA
Celldex Therapeutics CLDX	2.04 B	$ 32.24	-4.1 %	$ 2.14 B	USA
Aeglea BioTherapeutics AGLE	724 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	334 M	$ 1.4	-0.71 %	$ 360 M	USA
Applied Genetic Technologies Corporation AGTC	32.8 M	-	-	$ 26.5 M	USA
Allakos ALLK	114 M	-	-	$ 28.6 M	USA
Aptinyx APTX	9.48 M	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	467 M	$ 4.08	-2.16 %	$ 436 M	USA
Aravive ARAV	60.4 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	3.44 B	$ 24.21	-1.47 %	$ 3.08 B	USA
AIkido Pharma AIKI	19.6 M	-	1.93 %	$ 17.4 M	USA
Autolus Therapeutics plc AUTL	322 M	$ 1.49	1.36 %	$ 397 M	Britain
Aptose Biosciences APTO	2.32 M	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	148 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	56.3 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	7.72 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	15.8 M	$ 2.55	-0.78 %	$ 16 M	USA
InflaRx N.V. IFRX	149 M	$ 1.0	-2.91 %	$ 152 M	Germany
AstraZeneca PLC AZN	81.2 B	-	-	$ 96.9 B	Britain
Immutep Limited IMMP	1.95 B	$ 0.31	-2.52 %	$ 1.08 B	Australia
Akero Therapeutics AKRO	3.25 B	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	3.53 B	-	-	$ 867 M	Germany
Brainstorm Cell Therapeutics BCLI	6.33 M	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	253 B	-	0.49 %	$ 251 B	Cayman-islands
Akouos AKUS	172 M	-	0.23 %	$ 488 M	USA
Akari Therapeutics, Plc AKTX	8.08 B	$ 3.83	-2.3 %	$ 258 B	Britain
Allena Pharmaceuticals ALNA	71.4 M	-	3.16 %	$ 1.9 M	USA
Evogene Ltd. EVGN	66.3 M	$ 0.81	-1.16 %	$ 27.9 M	Israel
Baudax Bio BXRX	779 K	-	0.59 %	$ 63 K	USA
Alpine Immune Sciences ALPN	269 M	-	-	$ 2.17 B	USA
Cabaletta Bio CABA	283 M	$ 3.13	-1.26 %	$ 315 M	USA